Your browser doesn't support javascript.
loading
Gold conjugate-based liposomes with hybrid cluster bomb structure for liver cancer therapy.
Zhang, Ning; Chen, Huan; Liu, Ai-Yun; Shen, Jia-Jia; Shah, Vishva; Zhang, Can; Hong, Jin; Ding, Ya.
Afiliação
  • Zhang N; Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing 210009, China.
  • Chen H; Department of Biochemistry, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China.
  • Liu AY; Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing 210009, China.
  • Shen JJ; Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing 210009, China.
  • Shah V; Department of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, Ontario, Canada.
  • Zhang C; Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing 210009, China.
  • Hong J; Key Laboratory of Biomedical Functional Materials, School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.
  • Ding Y; Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing 210009, China. Electronic address: ayanju@163.com.
Biomaterials ; 74: 280-91, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26461120
ABSTRACT
Hybrid drug delivery system containing both organic and inorganic nanocarriers is expected to achieve its complementary advantages for the aim of improving the performance of antineoplastic drugs in tumor therapy. Here we report the use of liposomes and gold nanoparticles to construct a liposome with a hybrid Cluster Bomb structure and discuss its unique multi-order drug release property for liver tumor treatment. A very simple method is used for the hybrid liposome preparation and involves mixing two solutions containing liposomes loaded with either non-covalent or covalent Paclitaxel (PTX, namely free PTX or PTX-conjugated GNPs, respectively) by different ratio of volume (2575, 5050, 2575, v/v). Various mixed liposomes were tested to determine the optimal conditions for maximum drug delivery. The optimized liposome was then tested using xenograft Heps tumor-bearing mice and showed the best efficacy for chemotherapeutic inhibition of tumor at PTX liposome PTX-conjugated GNP liposome of 2575 ratio (v/v). This system allows for simple and easy preparation while providing a more accurate site- and time-release mode for tumor treatment using antitumor drugs.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Ouro / Lipossomos / Neoplasias Hepáticas Limite: Humans Idioma: En Revista: Biomaterials Ano de publicação: 2016 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Ouro / Lipossomos / Neoplasias Hepáticas Limite: Humans Idioma: En Revista: Biomaterials Ano de publicação: 2016 Tipo de documento: Article País de afiliação: China